$4.69
-0.20-4.09%
Last update: Nov 9, 4:00 PM
Entrada Therapeutics Inc
TRDANASDAQ
The average analyst price target for Entrada Therapeutics is $22.75, 385.1% above the current price. Of 4 analysts, 3 rate it Buy and 1 Hold. Targets range from $17 to $29. The latest change came on Jun 8, 2026, when Guggenheim lowered its price target on Entrada Therapeutics from $20 to $17 and kept a Buy rating.
Price Target Range — 9 Quarters
Analyst Consensus — 4 Analysts
Rating Trend — Last 9 Months
